Anbio Biotechnology Operating Lease, Right-of-Use Asset, Amortization Expense
Anbio Biotechnology (NNNN) reported Operating Lease, Right-of-Use Asset, Amortization Expense of $12.06 thousand for the 12-month period ending 2023-12-31, per its 20-F filed 2026-04-07.
Financial Statements › Cash Flow › Operating Activities
us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense · last filed 2026-04-07
| Period end | Operating Lease, Right-of-Use Asset, Amortization Expense 12 month |
|---|---|
| 2023-12-31 | $12.06K 20-F · filed 2026-04-07 |
| 2022-12-31 | $6.25K 20-F · filed 2025-04-28 |